palatin

Palatin begins bremelanotide phase 3 study for treatment of female sexual dysfunction Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential...